Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

Todd Neale

February 14, 2024

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

L.A. McKeown

November 20, 2023

News Features

Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good

Todd Neale

December 14, 2020

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

Caitlin E. Cox

January 08, 2018

Podcast TCTMD Talking Points

COLOR - A Multicenter Registry Looking at Lipid-Rich Plaque and 2-Year Outcomes After Stenting

October 18, 2017

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

Todd Neale

May 05, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

CME

Advertisement

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

COLOR - A Multicenter Registry Looking at Lipid-Rich Plaque and 2-Year Outcomes After Stenting

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Aspirin for the Interventionalist: More Than Meets the Eye

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content